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However, this displacement was larger for ventral seeds 
compared to dorsal seeds (see Fig. 1): 4.4±3.1mm versus 
1.7±2.6mm (p<0.001). Of the ventral seeds, cranial seeds 
showed larger displacements than caudal seeds: 5.3±3.1mm 
versus 3.5±3.1mm (p<0.001). 
 
 
Conclusions: Due to prostate volume changes and seed 
displacements after the seed implantation, a reliable 
quantitative assessment of dose-volume parameters for the 
prostate cannot be made at the end of the implantation 
procedure at the OR. A qualitative determination of possible 
cold spots, however, can be made if a potential displacement 
of ventral seed strands in caudal direction is considered.  
   
OC-0134   
Choline/PET CT and MRI detection of recurrences after I-
125 seed implant brachytherapy of prostate cancer 
T.H. Witteveen1, W.D. Heemsbergen1, L.M. Moonen1, M.J. 
Steggerda1, S. Heijmink2, U.A. Van der Heide1 
1The Netherlands Cancer Institute, Radiation Oncology, 
Amsterdam, The Netherlands  
2The Netherlands Cancer Institute, Radiology, Amsterdam, 
The Netherlands  
 
Purpose/Objective: For low (LR)- and intermediate-risk (IR) 
prostate cancer, I-125 seed implant is a highly successful 
treatment modality. However, a small proportion of patients 
show tumor recurrence at some point. Salvage options 
depend on the location of tumor progression. With multi-
parametric MRI and Choline PET, patterns of failure can be 
established. The purpose of this study was therefore to 
identify the location and timing of tumor progression after 
brachytherapy.  
Materials and Methods: Between January 2003 and January 
2011, 328 patients with Gleason ≤7, PSA <20, clinical stage 
T1-T2 and a maximum prostate volume of 60 cc, were 
implanted with I-125 seeds (145 Gy). Date of progression was 
scored at either increase of PSA >2 µg/L above nadir, or 
established recurrence by biopsy and/or imaging, whichever 
was first. A PSA bounce (>2 µg/L increase) with spontaneous 
recovery was not scored as progression. Diagnostic 
procedures (including bone scan, multi-parametric MRI, 
Choline/PET CT, biopsies) were performed in most cases as a 
part of routine follow-up after rising PSA levels, determining 
the location(s) of first relapse. Cumulative incidences were 
estimated using Kaplan-Meier analysis. 
Results: 
 
At a median follow-up of 4.9 years (range 0.3 – 10.4), 5-year 
freedom from failure was 92 % for LR (n=214) and 88 % for IR 
(n=114). Six patients showed a PSA bounce>2 µg/L increase. 
Tumor Relapse was scored in 30 patients; in 4 cases follow-up 
imaging was lacking due to severe comorbidity or a wait and 
see policy. The first relapse location(s) are summarized in Fig 
1 (n=26). Local failure within the gland as (part of) a first 
event occurred in 46 % of the identified failures (12/26) with 
an estimated cumulative 5y incidence of 3.9 % in LR and 3.5 
% in IR patients (Log Rank p=0.8). Local failure in the 
prostate only (all pathology confirmed) occurred in 7 cases 
after a median follow-up of 4.3y (range 1.5 – 7.0) and a 
median PSA nadir of 0.6 µg/L; in 5 cases salvage 
prostatectomy was performed afterwards. Increased uptake 
in the seminal vesicles on follow-up Choline/PET CT (n=6) 
was observed 2 to 6y post-implantation (n=1 pathology 
confirmed). Patients who were diagnosed with distant failure 
as first site (n=5) had early relapses within 2 years and a high 
nadir (1.9 – 13.9 µg/L). Cumulative 5y incidence of failures 
occurring completely outside the gland (n=14) was 3.5 % for 
LR and 6.2 % for IR patients, which was a non-significant 
difference (p=0.15). 
Conclusions: Using multi-parametric MRI and Choline/PET 
CT, patterns of failure after brachytherapy were identified. 
Options for salvage treatment could be adapted accordingly, 
improving patient care. For solitary recurrences a local 
salvage treatment, such as prostatectomy, may be effective. 
The cases of early tumor progression completely outside the 
prostate gland, suggest that pre-treatment screening with 
MRI may improve patient selection and outcome for 
brachytherapy.  
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Purpose/Objective: To demonstrate the application of a 
biologically based inverse optimization algorithm for low dose 
rate (LDR) prostate focal brachytherapy treatment planning.  
